Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Researchers from Harvard have developed a predictive model, called MELD-Plus, capable of identifying patients at high-risk for developing negative outcomes following a hospital admission for cirrhosis. Findings were published in PLOS One.
If the past 25 years in information technology has taught consumers anything, it's that devices have to be better, smaller an faster. A new microchip, which reportedly costs all of $10, may be able to improve ultrasonic capabilities.
The Affordable Care Act (ACA) did change physicians' total patient mix by health insurance status, with the percentage of uninsured patients shrinking and the average Medicaid patient load increasing in states that expanded eligibility.
A wearable device capable of detecting and characterizing seizures could improve care for patients with epilepsy, according to a study published in Epilepsia.
Scientists at École Polytechnique Fédérale de Lausanne, Switzerland have demonstrated that phantom body pain in paraplegic patients could be reduced by creating a bodily illusion using virtual reality (VR), according to a study published Neurology.
Researchers often collect social media data without the user's consent, which may stray outside ethical guidelines, according to a study published in Research Ethics.
Researchers from the University of Helsinki and the Helsinki University Hospital have developed artificial intelligence (AI) software capable of measuring EEG signals in preterm infants to estimate the brain's functional maturity, according to a study published in Scientific Reports.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.